- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 4.40 Å
- Oligo State
- hetero-3-3-3-3-3-mer
- Ligands
- 9 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN: alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN.2: 12 residues within 4Å:- Chain A: N.107, T.109
- Chain C: W.86, D.87, T.92
- Chain D: Y.33, D.56, N.58, R.102, W.113, F.114, T.115
1 PLIP interactions:1 interactions with chain D- Hydrogen bonds: D:D.56, D:Y.33, D:Y.33, D:R.102, D:T.115
NAG-NAG-BMA-MAN.16: 12 residues within 4Å:- Chain F: N.107, T.109
- Chain H: W.86, D.87, T.92
- Chain I: Y.33, D.56, N.58, R.102, W.113, F.114, T.115
1 PLIP interactions:1 interactions with chain I- Hydrogen bonds: I:D.56, I:Y.33, I:R.102, I:T.115
NAG-NAG-BMA-MAN.30: 12 residues within 4Å:- Chain K: N.107, T.109
- Chain M: W.86, D.87, T.92
- Chain N: Y.33, D.56, N.58, R.102, W.113, F.114, T.115
1 PLIP interactions:1 interactions with chain N- Hydrogen bonds: N:Y.33, N:Y.33, N:R.102, N:T.115
- 18 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG-NAG.4: 5 residues within 4Å:- Chain A: T.98, Q.100, S.120, N.122, K.133
No protein-ligand interaction detected (PLIP)NAG-NAG.8: 7 residues within 4Å:- Chain A: Q.263, N.265, N.301, V.302, S.303, V.414
- Ligands: NAG-NAG-BMA-MAN-MAN-MAN-MAN-MAN-MAN-MAN.10
No protein-ligand interaction detected (PLIP)NAG-NAG.11: 4 residues within 4Å:- Chain A: N.355, S.357
- Ligands: NAG-NAG.12, NAG.46
No protein-ligand interaction detected (PLIP)NAG-NAG.12: 3 residues within 4Å:- Chain A: N.361
- Ligands: NAG-NAG.11, NAG.46
No protein-ligand interaction detected (PLIP)NAG-NAG.13: 4 residues within 4Å:- Chain A: N.232, P.261, N.416
- Ligands: NAG-NAG-BMA-MAN-MAN.7
No protein-ligand interaction detected (PLIP)NAG-NAG.14: 4 residues within 4Å:- Chain A: N.429, N.430
- Chain E: R.44, Q.234
2 PLIP interactions:2 interactions with chain E- Hydrogen bonds: E:R.44, E:Q.234
NAG-NAG.18: 5 residues within 4Å:- Chain F: T.98, Q.100, S.120, N.122, K.133
No protein-ligand interaction detected (PLIP)NAG-NAG.22: 8 residues within 4Å:- Chain F: Q.263, N.265, N.301, V.302, S.303, S.381, V.414
- Ligands: NAG-NAG-BMA-MAN-MAN-MAN-MAN-MAN-MAN-MAN.24
No protein-ligand interaction detected (PLIP)NAG-NAG.25: 4 residues within 4Å:- Chain F: N.355, S.357
- Ligands: NAG-NAG.26, NAG.52
No protein-ligand interaction detected (PLIP)NAG-NAG.26: 3 residues within 4Å:- Chain F: N.361
- Ligands: NAG-NAG.25, NAG.52
No protein-ligand interaction detected (PLIP)NAG-NAG.27: 3 residues within 4Å:- Chain F: P.261, N.416
- Ligands: NAG-NAG-BMA-MAN-MAN.21
No protein-ligand interaction detected (PLIP)NAG-NAG.28: 4 residues within 4Å:- Chain F: N.429, N.430
- Chain J: R.44, Q.234
2 PLIP interactions:2 interactions with chain J- Hydrogen bonds: J:R.44, J:Q.234
NAG-NAG.32: 4 residues within 4Å:- Chain K: T.98, Q.100, N.122, K.133
No protein-ligand interaction detected (PLIP)NAG-NAG.36: 7 residues within 4Å:- Chain K: Q.263, N.265, N.301, V.302, S.303, V.414
- Ligands: NAG-NAG-BMA-MAN-MAN-MAN-MAN-MAN-MAN-MAN.38
No protein-ligand interaction detected (PLIP)NAG-NAG.39: 3 residues within 4Å:- Chain K: N.355
- Ligands: NAG-NAG.40, NAG.58
No protein-ligand interaction detected (PLIP)NAG-NAG.40: 3 residues within 4Å:- Chain K: N.361
- Ligands: NAG-NAG.39, NAG.58
No protein-ligand interaction detected (PLIP)NAG-NAG.41: 3 residues within 4Å:- Chain K: P.261, N.416
- Ligands: NAG-NAG-BMA-MAN-MAN.35
No protein-ligand interaction detected (PLIP)NAG-NAG.42: 4 residues within 4Å:- Chain K: N.429, N.430
- Chain O: R.44, Q.234
2 PLIP interactions:2 interactions with chain O- Hydrogen bonds: O:R.44, O:Q.234
- 6 x NAG- NAG- BMA- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN-MAN-MAN.5: 6 residues within 4Å:- Chain A: R.162, I.164, N.167
- Chain E: R.19, R.84
- Chain K: R.278
2 PLIP interactions:2 interactions with chain E- Hydrogen bonds: E:R.19, E:R.19, E:R.19
NAG-NAG-BMA-MAN-MAN-MAN-MAN.9: 6 residues within 4Å:- Chain A: N.271, N.272, T.273, I.292
- Chain C: G.63, T.64
1 PLIP interactions:1 interactions with chain A- Hydrophobic interactions: A:I.292
NAG-NAG-BMA-MAN-MAN-MAN-MAN.19: 6 residues within 4Å:- Chain A: R.278
- Chain F: R.162, I.164, N.167
- Chain J: R.19, R.84
2 PLIP interactions:2 interactions with chain J- Hydrogen bonds: J:R.19, J:R.19, J:R.19
NAG-NAG-BMA-MAN-MAN-MAN-MAN.23: 6 residues within 4Å:- Chain F: N.271, N.272, T.273, I.292
- Chain H: G.63, T.64
1 PLIP interactions:1 interactions with chain F- Hydrophobic interactions: F:I.292
NAG-NAG-BMA-MAN-MAN-MAN-MAN.33: 6 residues within 4Å:- Chain F: R.278
- Chain K: R.162, I.164, N.167
- Chain O: R.19, R.84
2 PLIP interactions:2 interactions with chain O- Hydrogen bonds: O:R.19, O:R.19, O:R.19
NAG-NAG-BMA-MAN-MAN-MAN-MAN.37: 6 residues within 4Å:- Chain K: N.271, N.272, T.273, I.292
- Chain M: G.63, T.64
1 PLIP interactions:1 interactions with chain K- Hydrophobic interactions: K:I.292
- 3 x NAG- NAG- BMA- MAN- MAN- MAN- MAN- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN-MAN-MAN-MAN-MAN-MAN-MAN.6: 10 residues within 4Å:- Chain A: N.204, T.206, G.207, P.208, H.321
- Chain E: S.168, R.204, W.205, G.206, A.207
1 PLIP interactions:1 interactions with chain E- Hydrogen bonds: E:R.204
NAG-NAG-BMA-MAN-MAN-MAN-MAN-MAN-MAN-MAN-MAN.20: 10 residues within 4Å:- Chain F: N.204, T.206, G.207, P.208, H.321
- Chain J: S.168, R.204, W.205, G.206, A.207
1 PLIP interactions:1 interactions with chain J- Hydrogen bonds: J:R.204
NAG-NAG-BMA-MAN-MAN-MAN-MAN-MAN-MAN-MAN-MAN.34: 10 residues within 4Å:- Chain K: N.204, T.206, G.207, P.208, H.321
- Chain O: S.168, R.204, W.205, G.206, A.207
1 PLIP interactions:1 interactions with chain O- Hydrogen bonds: O:R.204
- 3 x NAG- NAG- BMA- MAN- MAN- MAN- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN-MAN-MAN-MAN-MAN-MAN.10: 20 residues within 4Å:- Chain A: N.265, T.267, R.296, H.299, N.301, D.380, S.381, T.383
- Chain C: S.22, N.42, N.43, P.58, G.59, S.60
- Chain D: R.103, I.104, Y.105, G.106, V.107
- Ligands: NAG-NAG.8
2 PLIP interactions:2 interactions with chain A- Hydrogen bonds: A:R.296, A:R.296
NAG-NAG-BMA-MAN-MAN-MAN-MAN-MAN-MAN-MAN.24: 19 residues within 4Å:- Chain F: N.265, T.267, R.296, H.299, N.301, D.380, S.381, T.383
- Chain H: S.22, N.42, N.43, G.59, S.60
- Chain I: R.103, I.104, Y.105, G.106, V.107
- Ligands: NAG-NAG.22
2 PLIP interactions:2 interactions with chain F- Hydrogen bonds: F:R.296, F:R.296
NAG-NAG-BMA-MAN-MAN-MAN-MAN-MAN-MAN-MAN.38: 20 residues within 4Å:- Chain K: N.265, T.267, R.296, H.299, N.301, D.380, S.381, T.383
- Chain M: S.22, N.42, N.43, P.58, G.59, S.60
- Chain N: R.103, I.104, Y.105, G.106, V.107
- Ligands: NAG-NAG.36
2 PLIP interactions:2 interactions with chain K- Hydrogen bonds: K:R.296, K:R.296
- 18 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.43: 2 residues within 4Å:- Chain A: N.103, D.110
Ligand excluded by PLIPNAG.44: 5 residues within 4Å:- Chain A: E.245, N.246, T.248
- Chain E: G.169, Y.229
Ligand excluded by PLIPNAG.45: 2 residues within 4Å:- Chain A: N.308, W.364
Ligand excluded by PLIPNAG.46: 5 residues within 4Å:- Chain A: N.332, S.333, S.357
- Ligands: NAG-NAG.11, NAG-NAG.12
Ligand excluded by PLIPNAG.47: 2 residues within 4Å:- Chain B: N.100, S.102
Ligand excluded by PLIPNAG.48: 2 residues within 4Å:- Chain B: E.123, N.126
Ligand excluded by PLIPNAG.49: 2 residues within 4Å:- Chain F: N.103, D.110
Ligand excluded by PLIPNAG.50: 6 residues within 4Å:- Chain F: E.245, N.246, T.248
- Chain J: S.168, G.169, Y.229
Ligand excluded by PLIPNAG.51: 2 residues within 4Å:- Chain F: N.308, W.364
Ligand excluded by PLIPNAG.52: 5 residues within 4Å:- Chain F: N.332, S.333, S.357
- Ligands: NAG-NAG.25, NAG-NAG.26
Ligand excluded by PLIPNAG.53: 2 residues within 4Å:- Chain G: N.100, S.102
Ligand excluded by PLIPNAG.54: 2 residues within 4Å:- Chain G: E.123, N.126
Ligand excluded by PLIPNAG.55: 2 residues within 4Å:- Chain K: N.103, D.110
Ligand excluded by PLIPNAG.56: 5 residues within 4Å:- Chain K: E.245, N.246, T.248
- Chain O: G.169, Y.229
Ligand excluded by PLIPNAG.57: 2 residues within 4Å:- Chain K: N.308, W.364
Ligand excluded by PLIPNAG.58: 5 residues within 4Å:- Chain K: N.332, S.333, S.357
- Ligands: NAG-NAG.39, NAG-NAG.40
Ligand excluded by PLIPNAG.59: 2 residues within 4Å:- Chain L: N.100, S.102
Ligand excluded by PLIPNAG.60: 2 residues within 4Å:- Chain L: E.123, N.126
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Jardine, J.G. et al., Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design. Plos Pathog. (2016)
- Release Date
- 2016-08-17
- Peptides
- Envelope glycoprotein gp120: AFK
Envelope glycoprotein gp41: BGL
PGT122 light chain,Ig lambda-3 chain C regions: CHM
PGT122 heavy chain,IgG H chain: DIN
NIH45-46 single chain Fv: EJO - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
GF
AK
JB
BG
CL
KC
LH
EM
MD
HI
FN
NE
DJ
IO
O
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 4.40 Å
- Oligo State
- hetero-3-3-3-3-3-mer
- Ligands
- 9 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN: alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 18 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 6 x NAG- NAG- BMA- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)-[alpha-D-mannopyranose-(1-3)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN- MAN- MAN- MAN- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN- MAN- MAN- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 18 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Jardine, J.G. et al., Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design. Plos Pathog. (2016)
- Release Date
- 2016-08-17
- Peptides
- Envelope glycoprotein gp120: AFK
Envelope glycoprotein gp41: BGL
PGT122 light chain,Ig lambda-3 chain C regions: CHM
PGT122 heavy chain,IgG H chain: DIN
NIH45-46 single chain Fv: EJO - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
GF
AK
JB
BG
CL
KC
LH
EM
MD
HI
FN
NE
DJ
IO
O